BurakZeybekMDCritical Care Medicine

PubMed

• Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
  Dana M Roque, Eric R Siegel, Natalia Buza, Stefania Bellone, Dan-Arin Silasi, Gloria S Huang, Vaagn Andikyan, Mitchell Clark, Masoud Azodi, Peter E Schwartz, Gautam G ...> ;British Journal of Cancer. 2024 Apr 1
• Alterations in Pre/Post Oxygenator Flows Due to Fibrin Deposition in the CardioHelp System-A Case Report.
  Tyler Wahl, Angela Stokes, Caleb Varner, Burak Zeybek, Amit Bardia> ;The Journal of Extra-Corporeal Technology. 2022 Sep 1
• 3 citations
  Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
  Dana M Roque, Eric R Siegel, Natalia Buza, Stefania Bellone, Dan-Arin Silasi, Gloria S Huang, Vaagn Andikyan, Mitchell Clark, Masoud Azodi, Peter E Schwartz, Gautam G ...> ;British Journal of Cancer. 2022 Jun 1
• 28 citations
  A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
  Stefania Bellone, Dana M Roque, Eric R Siegel, Natalia Buza, Pei Hui, Elena Bonazzoli, Adele Guglielmi, Luca Zammataro, Nupur Nagarkatti, Samir Zaidi, Jungsoo Lee, Dan...> ;Cancer. 2022 Mar 15
• 8 citations
  DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
  Joan Tymon-Rosario, Elena Bonazzoli, Stefania Bellone, Aranzazu Manzano, Silvia Pelligra, Adele Guglielmi, Barbara Gnutti, Nupur Nagarkatti, Burak Zeybek, Paola Manara...> ;Gynecologic Oncology. 2021 Nov 1
• 12 citations
  Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.
  Joan Tymon-Rosario, Eric R. Siegel, Stefania Bellone, Justin Harold, Naomi N Adjei, Burak Zeybek, Dennis Mauricio, Gary Altwerger, Gulden Menderes, Elena Ratner, Mitch...> ;Gynecologic Oncology. 2021 Oct 1
• 8 citations
  Financial toxicity in patients with gynecologic malignancies: a cross sectional study
  Burak Zeybek, Emily Webster, Natalia Pogosian, Joan Tymon-Rosario, Alan Balch, Gary Altwerger, Mitchell Clark, Gulden Menderes, Gloria S. Huang, Masoud Azodi, Elena Ra...> ;Journal of Gynecologic Oncology. 2021 Jul 23
• 26 citations
  A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated charact...
  Stefania Bellone, Dana M. Roque, Eric R. Siegel, Natalia Buza, Pei Hui, Elena Bonazzoli, Adele Guglielmi, Luca Zammataro, Nupur Nagarkatti, Samir Zaidi, Jung-Soo Lee, ...> ;Annals of Oncology. 2021 Apr 28
• 28 citations
  Immunotherapy in Cervical Cancer.
  Dennis Mauricio, Burak Zeybek, Joan Tymon-Rosario, Justin Harold, Alessandro D. Santin> ;Current Oncology Reports. 2021 Apr 14
• 46 citations
  Integrated mutational landscape analysis of uterine leiomyosarcomas
  Jungmin Choi, Aranzazu Manzano, Weilai Dong, Stefania Bellone, Elena Bonazzoli, Luca Zammataro, Xiaotong Yao, Aditya Deshpande, Samir Zaidi, Adele Guglielmi, Barbara G...> ;Proceedings of the National Academy of Sciences of the United States of America. 2021 Apr 13
• Novel antibody-drug conjugates: current and future roles in gynecologic oncology.
  Joan Tymon-Rosario, Burak Zeybek, Alessandro D. Santin> ;Current Opinion in Obstetrics & Gynecology. 2021 Feb 1
• 3 citations
  Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer
  Dennis Mauricio, Justin Harold, Joan Tymon-Rosario, Burak Zeybek, Alessandro D. Santin> ;Expert Opinion on Biological Therapy. 2021 Jan 8
• 9 citations
  Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based study.
  Emily Webster, Ghanshyam Yadav, Stefan Gysler, Blair McNamara, Jonathan Black, Joan Tymon-Rosario, Burak Zeybek, Chanhee Han, Christopher Ke Arkfeld, Vaagn Andikyan, G...> ;Gynecologic Oncology Reports. 2020 Nov 2
• 2 citations
  Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.
  Elena Bonazzoli, Stefania Bellone, Luca Zammataro, Barbara Gnutti, Adele Guglielmi, Silvia Pelligra, Nupur Nagarkatti, Paola Manara, Joan Tymon-Rosario, Burak Zeybek, ...> ;Gynecologic Oncology. 2020 Jun 26
• 2 citations
  Opsoclonus-ataxia syndrome and mature ovarian teratoma in an adolescent
  Emily Webster, Joan Tymon-Rosario, Johanna D'Addario, Burak Zeybek, Elena Ratner> ;Gynecologic Oncology Reports. 2020 Jun 24
• 3 citations
  Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer.
  Emily Webster, Burak Zeybek, Joan Tymon-Rosario, Alessandro D. Santin> ;Oncoscience. 2020 Jun 8
• 2 citations
  Impact of timing on wound dressing removal after caesarean delivery: a multicentre, randomised controlled trial.
  Gokhan Sami Kilic, Erhan Demirdağ, Mehmet Fatih Findik, Omer Lutfi Tapisiz, Muhammet Erdal Sak, Orhan Altinboga, Sibel Sak, Bekir Serdar Unlu, Mehmet Sıddık Evsen, Bur...> ;Journal of Obstetrics and Gynaecology. 2021 Apr 3
• 29 citations
  Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study
  Ana M. Rodriguez, Burak Zeybek, Micah Vaughn, Jordan Westra, Sapna Kaul, Jane R. Montealegre, Yu Li Lin, Yong Fang Kuo> ;Cancer. 2020 Apr 15
• 17 citations
  Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial aden...
  Emanuele Perrone, Paola Manara, Salvatore Lopez, Stefania Bellone, Elena Bonazzoli, Aranzazu Manzano, Luca Zammataro, Anna Bianchi, Burak Zeybek, Natalia Buza, Joan Ty...> ;Molecular Oncology. 2020 Mar 1
• 4 citations
  Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma.
  Silvia Pelligra, Natalia Buza, Pei Hui, Stefania Bellone, Burak Zeybek, Elena Ratner, Peter E. Schwartz, Giovanni Scambia, Alessandro D. Santin> ;Gynecologic Oncology Reports. 2020 Feb 25
• 27 citations
  Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irin...
  Emanuele Perrone, Salvatore Lopez, Burak Zeybek, Stefania Bellone, Elena Bonazzoli, Silvia Pelligra, Luca Zammataro, Aranzazu Manzano, Paola Manara, Anna Bianchi, Nata...> ;Frontiers in Oncology. 2020 Feb 12
• 26 citations
  Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.
  Salvatore Lopez, Emanuele Perrone, Stefania Bellone, Elena Bonazzoli, Burak Zeybek, Chanhee Han, Joan Tymon-Rosario, Gary Altwerger, Gulden Menderes, Anna Bianchi, Luc...> ;Oncotarget. 2020 Feb 4
• 15 citations
  In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
  Chanhee Han, Emanuele Perrone, Burak Zeybek, Stefania Bellone, Joan Tymon-Rosario, Gary Altwerger, Gulden Menderes, Jacqueline Feinberg, Kaitlin Haines, Mariana Espina...> ;Gynecologic Oncology. 2020 Feb 1
• 22 citations
  Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies.
  Britt K. Erickson, Burak Zeybek, Alessandro D. Santin, Amanda N. Fader> ;Current Opinion in Obstetrics & Gynecology. 2020 Feb 1
• 23 citations
  Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.
  Burak Zeybek, Aranzazu Manzano, Anna Bianchi, Elena Bonazzoli, Stefania Bellone, Natalia Buza, Pei Hui, Salvatore Lopez, Emanuele Perrone, Paola Manara, Luca Zammataro...> ;Scientific Reports. 2020 Jan 22
• Join now to see all

Lectures

• Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. 
  2019 ASCO Annual Meeting - 6/1/2019